Access & Cost

How Much Do GLP-1 Medications Cost Without Insurance in 2026?

Self-pay GLP-1 treatment in 2026 runs from roughly

50 to $550 per month depending on the product, the dose, and the channel. Manufacturer direct programs, savings cards, oral tablets, and compounded preparations each price differently, and the cheapest path changes as your dose changes. Here is the map.

Reviewed by board-certified physicians · Published 2026-08-28 · Updated 2026-08-28 · 10 min read

Key facts

  • List prices near
    ,000 a month are mostly fiction for self-pay patients now. Manufacturer direct programs sell well below list.
  • As of mid-2026, manufacturer self-pay programs for the branded injectables have generally run in the low hundreds per month for starting doses, rising with dose. Published prices change, so check the manufacturer program pages for today's numbers.
  • The new oral GLP-1 tablets launched with introductory self-pay pricing in the
    49 per month range, with ongoing prices higher.
  • Compounded tirzepatide from state-licensed pharmacies generally prices below the branded injectables, most visibly at higher doses.
  • The per-month number is not the comparison that matters. Cost per month at YOUR dose over a full titration is.

Why is GLP-1 pricing so confusing?

Because there is no single price. The same medication can carry a four-figure list price, a mid-hundreds manufacturer direct price, a double-digit copay with the right insurance and savings card, and a different number again at each dose step. Sellers quote whichever number flatters them. The way through is to compare one thing: what you would pay per month, at your dose, through each channel actually available to you.

What do the branded injectables cost self-pay?

Both manufacturers now run direct-to-patient self-pay programs, born in 2024 and 2025 when they needed an answer to compounding. Zepbound® is sold through the manufacturer's direct channel as single-dose vials at prices meaningfully below the pen list price, tiered by dose, with the lower strengths in the high

00s to low $300s per month range and higher strengths costing more, as of mid-2026. Wegovy® has an equivalent direct program in the same general territory.

Two program details catch people out. Direct-program pricing often requires refilling within a set window to keep the discounted rate, and vials mean drawing your dose with a syringe rather than clicking a pen. The prices are also revised periodically, in both directions, so treat any specific figure you read, including here, as a snapshot to verify against the program page before deciding.

What do the new GLP-1 pills cost?

The oral era opened between December 2025 and April 2026 with the approval of an oral semaglutide tablet for weight management (Wegovy Pill®) and Foundayo, the first small-molecule GLP-1 pill (orforglipron). Both launched with aggressive introductory self-pay pricing around

49 for early fills, moving to roughly $300 to $350 per month at ongoing prices, with savings cards for eligible commercially insured patients and, unusually, a discount card program aimed at Medicare patients for the small-molecule pill.

Introductory pricing is exactly that. When comparing a pill against an injectable, compare the ongoing price, not the launch offer, and weigh the differences covered in our pill vs injection guide.

3/mo CHROMA23+ Membership unlocks it at one clear price, medication priced separately and always shown.

Start the free assessment · Explore weight loss treatments

Where does compounded tirzepatide fit in the math?

Patient-specific compounded tirzepatide from a state-licensed pharmacy generally prices below the branded options, and the gap widens at higher doses, because compounded pricing tends to scale gently with milligrams while branded tiers step up more steeply. At starting doses, the manufacturer direct programs have narrowed the difference considerably.

Compounded preparations are not FDA-approved, the trial data belongs to the branded products, and eligibility runs through a physician's individualized prescription rather than a shopping cart. Cost alone is not a qualifying clinical reason under the 503A rules, which is covered in our legality explainer. Treat compounded pricing as one input to a clinical conversation, not a menu price.

Why does my dose change the answer?

Nearly everyone starts at a low dose and titrates up over several months. Channels that look identical at 2.5 mg can diverge by thousands of dollars a year at 10 or 15 mg equivalents, because branded pricing steps up by tier while other channels scale differently. Before committing, price the whole first year of your likely titration path, not the first month.

This is also why the cheapest first month is a poor selection criterion. A launch offer or trial price tells you what month one costs. Your treatment, if it works for you, is not one month long.

What should a clear price actually include?

Whatever channel you choose, you should be able to see, before paying: the medication price at your dose, any membership or platform fee stated separately, the physician evaluation cost, and shipping. If a platform bundles those into a single number that is impossible to decompose, or advertises a price that quietly excludes the physician or the medication, walk.

CHROMA23® prices the pieces separately on purpose: the assessment is free, the CHROMA23+ Membership is 3 a month, and every medication price is shown next to it before checkout. All costs shown, nothing inflated.

Frequently asked questions

Is anything under 00 a month legitimate in 2026?

Sometimes. Introductory pill pricing, some starting-dose programs, and some compounded prescriptions land there legitimately. What should raise questions is a rock-bottom price with no physician evaluation, no named pharmacy, or a seller describing prescription products as supplements. The regulated channels compete hard now; the discount for leaving the regulated system is smaller than it has ever been, and the risk is not.

Do the manufacturer savings cards work without insurance?

The standard savings cards are generally for commercially insured patients, with reduced benefits when coverage excludes the drug. The direct-purchase programs are the manufacturers' actual self-pay channel. They are separate mechanisms, and mixing them up is the most common pricing confusion of all.

Why did my quoted price change after a few months?

Usually one of three reasons: your dose stepped up a tier, an introductory or refill-window condition lapsed, or the program itself revised prices. All three are checkable. Ask which one applies before assuming anything else.

Does CHROMA23® charge for the physician visit?

The assessment is free. The membership is 3 a month, medication is always priced separately, and every cost, including the physician review, is shown before you pay. Nothing is bundled into a number you cannot decompose.

About CHROMA23®

CHROMA23® is a clinical weight loss platform built on prescription protocols: injectables, oral medicine, and the protocols that come next, under one 3 membership. Every prescription decision is made by an independent, board-certified physician licensed in the patient's state, and every medication is dispensed by a state-licensed pharmacy. The assessment is free. The membership is 3. The medicine is real. The physician is real.

Sources

  1. LillyDirect self-pay pricing for Zepbound®
  2. NovoCare pharmacy: Wegovy® direct pricing
  3. KFF: employer perspectives on covering GLP-1s for weight loss (2025 Employer Health Benefits Survey)
  4. FDA press announcement: approval of orforglipron (Foundayo), April 2026
  5. Eli Lilly: Foundayo approval announcement
  6. Novo Nordisk: Wegovy pill approved in the US as first oral GLP-1 for weight management (Dec 2025)

Keep reading

This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Compounded medications are not FDA-approved. Always consult a board-certified physician about your individual situation. Figures from named clinical trials describe study populations; individual results vary and are not typical.

All articles